Genematrix Reports Q1 Sales of 2.5 Billion KRW... "Exports on the Rise"

Genematrix announced on May 15 that it recorded sales of 2,496 million KRW, an operating loss of 288 million KRW, and a net loss of 786 million KRW in the first quarter.

Sales increased by 38.2% compared to the same period last year, while operating loss and net loss decreased by 68.5% and 57.5%, respectively, resulting in a significant improvement in profitability. Overseas sales rose by 87.2% year-on-year, driven by a focus on exporting the high-performance multiplex molecular diagnostic product 'NeoPlex'.

Among its business segments, sales from the molecular diagnostics business grew by 66.5% year-on-year, leading overall sales growth. Within the NeoPlex product line, the respiratory infection (RI) product group?comprising three products: pneumonia infection (RB) products including Mycoplasma pneumoniae and Bordetella pertussis, respiratory virus infection (RV) products, and tuberculosis and nontuberculous mycobacteria infection (TB·NTM) products?achieved sales growth of 334.2% and export growth of 451.4%. Notably, sales of the tuberculosis and nontuberculous mycobacteria products surged by 615.9%, demonstrating remarkable growth.

Kim Soo-ok, CEO of Genematrix, stated, "The export of the NeoPlex product line, which offers differentiated multiplex molecular diagnostic performance, continues to show sustained growth. This is possible thanks to Genematrix's proprietary platform technology, and we will continue to focus all our capabilities on enhancing the global brand awareness of NeoPlex products and expanding overseas sales."